Login to Your Account

FDA concerns not ‘soli’ CMC, liver-toxicity CRL proposing major safety trial

By Randy Osborne
Staff Writer

Thursday, December 29, 2016

Given the frets of an adcom, the FDA’s CRL to Cempra Inc. for ketolide antibiotic solithromycin wasn’t much of a surprise.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription